BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31697992)

  • 1. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study.
    Ofori-Asenso R; Ilomaki J; Chin KL; Mazidi M; Zomer E; Bell JS; Magliano DJ; Liew D
    Diabetes Res Clin Pract; 2019 Dec; 158():107909. PubMed ID: 31697992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL; Worley K; Meah Y; Everhart D
    J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes.
    Ogundipe O; Mazidi M; Chin KL; Gor D; McGovern A; Sahle BW; Jermendy G; Korhonen MJ; Appiah B; Ademi Z; De Bruin ML; Liew D; Ofori-Asenso R
    Acta Diabetol; 2021 Jan; 58(1):39-46. PubMed ID: 32809070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
    Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
    PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
    Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
    J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study.
    Ofori-Asenso R; Liew D; Lalic S; Mazidi M; Magliano DJ; Ademi Z; Bell JS; Ilomaki J
    Adv Ther; 2019 Nov; 36(11):3265-3278. PubMed ID: 31482509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
    Tebboth A; Lee S; Scowcroft A; Bingham-Gardiner P; Spencer W; Bolodeoku J; Hassan SW
    Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors.
    Farr AM; Sheehan JJ; Brouillette M; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2016 Jan; 33(1):68-81. PubMed ID: 26724938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S; Nwosu AC; Mukherjee D; Hernandez GT
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK; Drayna CC; McDermott MT
    Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
    Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
    J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients.
    Esposito K; Chiodini P; Maiorino MI; Capuano A; Cozzolino D; Petrizzo M; Bellastella G; Giugliano D
    BMJ Open; 2015 Feb; 5(2):e005892. PubMed ID: 25687897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
    Nishida Y; Takahashi Y; Tezuka K; Akimoto H; Nakayama T; Asai S
    BMC Pharmacol Toxicol; 2020 Apr; 21(1):28. PubMed ID: 32317005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
    Fu AZ; Johnston SS; Ghannam A; Tsai K; Cappell K; Fowler R; Riehle E; Cole AL; Kalsekar I; Sheehan J
    Diabetes Care; 2016 May; 39(5):726-34. PubMed ID: 26740636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
    Guo WQ; Li L; Su Q; Dai WR; Ye ZL
    Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
    Vaduganathan M; Singh A; Sharma A; Januzzi JL; Scirica BM; Butler J; Zannad F; McGuire DK; Cannon CP; Bhatt DL
    Am J Cardiol; 2020 May; 125(10):1577-1581. PubMed ID: 32245636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
    Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.